Share Name Share Symbol Market Type Share ISIN Share Description
Astrazeneca Plc LSE:AZN London Ordinary Share GB0009895292 ORD SHS $0.25
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -49.00p -0.72% 6,772.00p 6,784.00p 6,786.00p 6,860.00p 6,763.00p 6,821.00p 1,437,883 16:35:11
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 17,322.1 1,562.8 133.3 51.7 88,834

AstraZeneca PLC Directorate Change

19/08/2019 7:00am

UK Regulatory (RNS & others)


Astrazeneca (LSE:AZN)
Historical Stock Chart

2 Months : From Aug 2019 to Oct 2019

Click Here for more Astrazeneca Charts.

TIDMAZN

RNS Number : 4087J

AstraZeneca PLC

19 August 2019

19 August 2019 07:00 BST

AstraZeneca appoints Michel Demaré to its Board of Directors

AstraZeneca today announced that, with effect from 1 September 2019, Michel Demaré is appointed as a Non-Executive Director and a member of the Audit Committee.

Leif Johansson, Chairman of AstraZeneca, said: "We are delighted to appoint Michel Demaré as a Director. He has a great deal of industrial, financial and board-level experience across a range of sectors including science and technology, that will enable him to contribute well to the work of our Board and Audit Committee."

Michel Demaré is a Non-Executive Director of Vodafone Group Plc and a member of the Supervisory Board of Louis Dreyfus Company Holdings BV. He is Vice-Chairman and Chairman-designate of the IMD executive business school in Lausanne, and a member of the Advisory Board of the Department of Banking and Finance at the University of Zurich.

Mr Demaré was Vice-Chairman of UBS Group AG from 2010 to 2019, Chairman of Syngenta and the Syngenta Foundation for Sustainable Agriculture from 2013 to 2017 and Chairman of SwissHoldings from 2013 to 2015.

Mr Demaré joined ABB Ltd in 2005 as Chief Financial Officer (CFO) and member of the Group Executive Committee. For most of 2008, he acted as the interim Chief Executive Officer of ABB. From late 2008 to 2011, he combined his role as CFO with that of President of Global Markets.

He joined ABB from Baxter International Inc., where he was CFO Europe from 2002 to 2005. Prior to that, he spent 18 years at the Dow Chemical Company, holding various treasury and risk management positions in Belgium, France, the US and Switzerland. Between 1997 and 2002, Mr Demaré was CFO of the Global Polyolefins and Elastomers division. He began his career as a banking officer in the multinational banking division of Continental Illinois' Belgian subsidiary.

Mr Demaré graduated with an MBA from the Katholieke Universiteit Leuven, Belgium, and holds a degree in applied economics from the Université Catholique de Louvain, Belgium.

Except as set out above, no disclosure obligations arise under paragraphs (1) to (6) of LR 9.6.13 R of the UK Listing Authority's Listing Rules in respect of this appointment.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, CVRM and Respiratory. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit astrazeneca.com and follow us on Twitter @AstraZeneca.

 
 Media Relations 
 Gonzalo Viña                                                                         +44 203 749 5916 
 Rob Skelding                           Oncology                                           +44 203 749 5821 
 Rebecca Einhorn                        Oncology                                           +1 301 518 4122 
 Matt Kent                              BioPharmaceuticals                                 +44 203 749 5906 
 Jennifer Hursit                        Other                                              +44 203 749 5762 
 Christina Malmberg Hägerstrand    Sweden                                             +46 8 552 53 106 
 Michele Meixell                        US                                                 +1 302 885 2677 
 
 Investor Relations 
 Thomas Kudsk Larsen                                                                       +44 203 749 5712 
 Henry Wheeler                          Oncology                                           +44 203 749 5797 
 Christer Gruvris                       BioPharmaceuticals (cardiovascular, metabolism)    +44 203 749 5711 
 Nick Stone                             BioPharmaceuticals (respiratory, renal)            +44 203 749 5716 
 Josie Afolabi                          Other medicines                                    +44 203 749 5631 
 Craig Marks                            Finance, fixed income                              +44 7881 615 764 
 Jennifer Kretzmann                     Corporate access, retail investors                 +44 203 749 5824 
 US toll-free                                                                              +1 866 381 72 77 
 

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOASFUSWAFUSEFA

(END) Dow Jones Newswires

August 19, 2019 02:00 ET (06:00 GMT)

1 Year Astrazeneca Chart

1 Year Astrazeneca Chart

1 Month Astrazeneca Chart

1 Month Astrazeneca Chart
Your Recent History
LSE
AZN
Astrazenec..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191019 00:26:11